$0.00
−78.05%Price chart
Jul 27Jul 30Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25
Key dataAug 25, 2026
Open$0.23
From 52W high−99.76%
Volume258659.00
Market cap$142481.96
P/E (TTM)—
P/S (TTM)0.1x
Div yield—
Key dataAug 25, 2026
Open
$0.23
From 52W high
−99.76%
Volume
258659.00
Market cap
$142481.96
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
32.4
MomentumView details →
1D Return
−78.05%
YTD Return
−99.04%
SummaryUpdated Jun 1, 2026
Humacyte, Inc. (NASDAQ:HUMA) is a clinical-stage biotechnology company founded in 2004 and headquartered in Durham, North Carolina. The company went public in December 2020 and specializes in developing bioengineered human tissues for vascular repair and replacement applications. Humacyte has achieved its first commercial milestone with the FDA approval of its flagship product Symvess in 2024 for treating extremity vascular trauma, marking the transition from a pure research and development company to one generating initial commercial revenues.
Similar companies
Latest newsMore news →
Humacyte, Inc. shares closed at $0.40, down 6.5% from the previous trading day.8h agoHumacyte, Inc. reported that the number of hospitals ordering Symvess increased 44% in the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.5d agoHumacyte, Inc. shares fell 7.88% to $0.36 from the prior session's close.6d ago